cisplatin + gemcitabine + nimotuzumab

Cisplatin + gemcitabine + nimotuzumab is a combination regimen used primarily in the treatment of advanced cancers, notably non-small-cell lung cancer (NSCLC) and pancreatic cancer. Cisplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis. Gemcitabine is a nucleoside analog that inhibits DNA synthesis, leading to cell death. Nimotuzumab is a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking ligand binding and downstream signaling involved in tumor proliferation and survival. This combination leverages cytotoxic chemotherapy with targeted anti-EGFR therapy to enhance antitumor efficacy, particularly in patients with EGFR amplification or KRAS wild-type tumors[1][2][3][5].